Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
JANX is expected to report earnings to rise 79.44% to -69 cents per share on March 06
Q4'25
Est.
$-0.70
Q3'25
Beat
by $0.23
Q2'25
Missed
by $0.09
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.07
The last earnings report on November 06 showed earnings per share of -38 cents, beating the estimate of -62 cents. With 787.31K shares outstanding, the current market capitalization sits at 1.65B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. JANX showed earnings on November 06, 2025. You can read more about the earnings report here.